Friday, July 10, 2026

Drug profile · INN

apraclonidine hydrochloride

apraclonidine hydrochloride (IOPIDINE) is a adrenergic receptor alpha-2 agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — apraclonidine hydrochloride
US status
approved
Class
Route
OPHTHALMIC
Patents
0
Programs
0
Data quality
0.84

Quick answer

apraclonidine hydrochloride (IOPIDINE) is a adrenergic receptor alpha-2 agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN apraclonidine hydrochloride
Brand IOPIDINE
Mechanism Adrenergic receptor alpha-2 agonist
Target Adrenergic receptor alpha-2
Route OPHTHALMIC
Formulation SOLUTION/DROPS

Mechanism of action

Adrenergic receptor alpha-2 agonist

Primary target: Adrenergic receptor alpha-2

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. brimonidine tartrate Adrenergic receptor alpha-2 agonist
  2. clonidine hydrochloride Adrenergic receptor alpha-2 agonist
  3. dexmedetomidine hydrochloride Adrenergic receptor alpha-2 agonist
  4. guanfacine hydrochloride Adrenergic receptor alpha-2 agonist
  5. methyldopa Adrenergic receptor alpha-2 agonist
  6. methyldopate hydrochloride Adrenergic receptor alpha-2 agonist

Frequently asked questions

What is apraclonidine hydrochloride?

apraclonidine hydrochloride (IOPIDINE) is a adrenergic receptor alpha-2 agonist. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for apraclonidine hydrochloride?

IOPIDINE is a marketed brand name for apraclonidine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of apraclonidine hydrochloride?

apraclonidine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.